1. Home
  2. MPLT vs VIR Comparison

MPLT vs VIR Comparison

Compare MPLT & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$19.86

Market Cap

911.8M

Sector

Health Care

ML Signal

N/A

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$5.99

Market Cap

773.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPLT
VIR
Founded
2018
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
911.8M
773.5M
IPO Year
2025
2019

Fundamental Metrics

Financial Performance
Metric
MPLT
VIR
Price
$19.86
$5.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
11
Target Price
$31.00
$25.73
AVG Volume (30 Days)
290.1K
1.9M
Earning Date
12-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,860,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$48.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.24
$4.16
52 Week High
$21.55
$14.45

Technical Indicators

Market Signals
Indicator
MPLT
VIR
Relative Strength Index (RSI) N/A 45.54
Support Level N/A $6.49
Resistance Level N/A $6.75
Average True Range (ATR) 0.00 0.48
MACD 0.00 -0.06
Stochastic Oscillator 0.00 31.99

Price Performance

Historical Comparison
MPLT
VIR

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Share on Social Networks: